- -
-
Ključne reči:
-
Sažetak
-
Reference
References
1. Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet, 2023;401(10387):1531-1544.
2. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet, 2016;388(10061):2783-2795.
3. Nabhan F, Dedhia PH, Ringel MD. Thyroid cancer, recent advances in diagnosis and therapy. International Journal of Cancer, 2021;149(5):984-992.
4. Coca-Pelaz A, Shah JP, Hernandez-Prera JC, Ghossein RA, Rodrigo JP, Hartl DM, Olsen KD, Shaha AR, Zafereo M, Suarez C, Nixon IJ, Randolph GW, Mäkitie AA, Kowalski LP, Vander Poorten V, Sanabria A, Guntinas-Lichius O, Simo R, Zbären P, Angelos P, Khafif A, Rinaldo A, Ferlito A. Papillary thyroid cancer-aggressive variants and impact on management: a narrative review. Advances in Therapy, 2020;37(7):3112-3128.
5. Pace-Asciak P, Russell JO, Tufano RP. The treatment of thyroid cancer with radiofrequency ablation. Techniques in Vascular and Interventional Radiology, 2022;25(2):100825(1-5).
6. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer-treatment: state of the art. International Journal of Molecular Sciences, 2017;18(6):1292(1-17).
7. Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treatment Reviews, 2022;106:102380(1-11).
8. Conzo G, Mauriello C, Docimo G, Gambardella C, Thomas G, Cavallo F, Tartaglia E, Napolitano S, Varriale R, Rossetti G, Fei L, Santini L. Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery. International Journal of Surgery, 2014;12 Suppl 1:S194-7.
9. Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, Jiang L, Huang P, Zhang Y, Ge M. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy. Drug Resistance Updates, 2023;68:100939(1-22).
10. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, Borget I. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. The New England Journal of Medicine, 2022;386(10):923-932.
11. Shen H, Zhu R, Liu Y, Hong Y, Ge J, Xuan J, Niu W, Yu X, Qin JJ, Li Q. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resistance Updates, 2024;72:101013(1-31).
12. Iwano S, Ito S, Kamiya S, Ito R, Kato K, Naganawa S. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer. Nagoya Journal of Medical Science, 2020;82(2):205-215.
13. Giovanella L, van Nostrand D. Advanced differentiated thyroid cancer: when to stop radioiodine?. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2019;63(3):267-270.
14. Estorch M, Mitjavila M, Muros MA, Caballero E; en nombre del Grupo de Trabajo de Endocrinología de la SEMNIM. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019;38(3):195-203.
15. Larson SM, Osborne JR, Grewal RK, Tuttle RM. Redifferentiating thyroid cancer: selumetinib-enhanced radioiodine uptake in thyroid cancer. Molecular Imaging and Radionuclide Therapy, 2017;26(Suppl 1):80-86.
16. Dotinga M, Vriens D, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets-Schneider P, Pool M, Rietbergen DDD, de Geus-Oei LF, Kapiteijn E. Reinducing radioiodine-sensitivity in radioiodine-refractory thyroid cancer using lenvatinib (RESET): study protocol for a single-center, open label phase II trial. Diagnostics (Basel), 2022;12(12):3154(1-14).
17. Song E, Kim M, Kim EY, Kim BH, Shin DY, Kang HC, Ahn BC, Kim WB, Shong YK, Jeon MJ, Lim DJ. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in korea. Thyroid: official journal of the American Thyroid Association, 2020;30(5):732-738.
18. Kim M, Jin M, Jeon MJ, Kim EY, Shin DY, Lim DJ, Kim BH, Kang HC, Kim WB, Shong YK, Kim HK, Kim WG. Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid: official journal of the American Thyroid Association, 2023;33(1):91-99.
19. Zhang S, Zhong M, Zhu H, You Q, Yuan H, Li Y. Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway. Cancer Genetics, 2023;278-279:71-78.
20. Liu H, Tang T. A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value. American Journal of Translational Research, 2023;15(3):2140-2155.
21. Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H. Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid : Official Journal of the American Thyroid Association, 2006;16(3):281-8.
22. Buryk MA, Simons JP, Picarsic J, Monaco SE, Ozolek JA, Joyce J, Gurtunca N, Nikiforov YE, Feldman Witchel S. Can malignant thyroid nodules be distinguished from benign thyroid nodules in children and adolescents by clinical characteristics? A review of 89 pediatric patients with thyroid nodules. Thyroid : Official Journal of the American Thyroid Association, 2015;25(4):392-400.
23. Dotinga M, Vriens D, van Velden F, Heijmen L, Nagarajah J, Hicks R, Kapiteijn E, de Geus-Oei LF. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020;64(3):250-264.
24. Hengrui L. An example of toxic medicine used in traditional chinese medicine for cancer treatment. Journal of Traditional Chinese Medicine = Chung i tsa Chih Ying wen pan, 2023;43(2):209-210.
1. Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet, 2023;401(10387):1531-1544.
2. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet, 2016;388(10061):2783-2795.
3. Nabhan F, Dedhia PH, Ringel MD. Thyroid cancer, recent advances in diagnosis and therapy. International Journal of Cancer, 2021;149(5):984-992.
4. Coca-Pelaz A, Shah JP, Hernandez-Prera JC, Ghossein RA, Rodrigo JP, Hartl DM, Olsen KD, Shaha AR, Zafereo M, Suarez C, Nixon IJ, Randolph GW, Mäkitie AA, Kowalski LP, Vander Poorten V, Sanabria A, Guntinas-Lichius O, Simo R, Zbären P, Angelos P, Khafif A, Rinaldo A, Ferlito A. Papillary thyroid cancer-aggressive variants and impact on management: a narrative review. Advances in Therapy, 2020;37(7):3112-3128.
5. Pace-Asciak P, Russell JO, Tufano RP. The treatment of thyroid cancer with radiofrequency ablation. Techniques in Vascular and Interventional Radiology, 2022;25(2):100825(1-5).
6. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer-treatment: state of the art. International Journal of Molecular Sciences, 2017;18(6):1292(1-17).
7. Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treatment Reviews, 2022;106:102380(1-11).
8. Conzo G, Mauriello C, Docimo G, Gambardella C, Thomas G, Cavallo F, Tartaglia E, Napolitano S, Varriale R, Rossetti G, Fei L, Santini L. Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery. International Journal of Surgery, 2014;12 Suppl 1:S194-7.
9. Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, Jiang L, Huang P, Zhang Y, Ge M. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy. Drug Resistance Updates, 2023;68:100939(1-22).
10. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, Borget I. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. The New England Journal of Medicine, 2022;386(10):923-932.
11. Shen H, Zhu R, Liu Y, Hong Y, Ge J, Xuan J, Niu W, Yu X, Qin JJ, Li Q. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resistance Updates, 2024;72:101013(1-31).
12. Iwano S, Ito S, Kamiya S, Ito R, Kato K, Naganawa S. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer. Nagoya Journal of Medical Science, 2020;82(2):205-215.
13. Giovanella L, van Nostrand D. Advanced differentiated thyroid cancer: when to stop radioiodine?. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2019;63(3):267-270.
14. Estorch M, Mitjavila M, Muros MA, Caballero E; en nombre del Grupo de Trabajo de Endocrinología de la SEMNIM. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019;38(3):195-203.
15. Larson SM, Osborne JR, Grewal RK, Tuttle RM. Redifferentiating thyroid cancer: selumetinib-enhanced radioiodine uptake in thyroid cancer. Molecular Imaging and Radionuclide Therapy, 2017;26(Suppl 1):80-86.
16. Dotinga M, Vriens D, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets-Schneider P, Pool M, Rietbergen DDD, de Geus-Oei LF, Kapiteijn E. Reinducing radioiodine-sensitivity in radioiodine-refractory thyroid cancer using lenvatinib (RESET): study protocol for a single-center, open label phase II trial. Diagnostics (Basel), 2022;12(12):3154(1-14).
17. Song E, Kim M, Kim EY, Kim BH, Shin DY, Kang HC, Ahn BC, Kim WB, Shong YK, Jeon MJ, Lim DJ. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in korea. Thyroid: official journal of the American Thyroid Association, 2020;30(5):732-738.
18. Kim M, Jin M, Jeon MJ, Kim EY, Shin DY, Lim DJ, Kim BH, Kang HC, Kim WB, Shong YK, Kim HK, Kim WG. Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid: official journal of the American Thyroid Association, 2023;33(1):91-99.
19. Zhang S, Zhong M, Zhu H, You Q, Yuan H, Li Y. Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway. Cancer Genetics, 2023;278-279:71-78.
20. Liu H, Tang T. A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value. American Journal of Translational Research, 2023;15(3):2140-2155.
21. Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H. Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid : Official Journal of the American Thyroid Association, 2006;16(3):281-8.
22. Buryk MA, Simons JP, Picarsic J, Monaco SE, Ozolek JA, Joyce J, Gurtunca N, Nikiforov YE, Feldman Witchel S. Can malignant thyroid nodules be distinguished from benign thyroid nodules in children and adolescents by clinical characteristics? A review of 89 pediatric patients with thyroid nodules. Thyroid : Official Journal of the American Thyroid Association, 2015;25(4):392-400.
23. Dotinga M, Vriens D, van Velden F, Heijmen L, Nagarajah J, Hicks R, Kapiteijn E, de Geus-Oei LF. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020;64(3):250-264.
24. Hengrui L. An example of toxic medicine used in traditional chinese medicine for cancer treatment. Journal of Traditional Chinese Medicine = Chung i tsa Chih Ying wen pan, 2023;43(2):209-210.
Objavljeno
2025/10/03
Broj časopisa
Rubrika
Original paper
Sva prava zadržana (c) 2025 Bingliang Miao
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.